Zymeworks(ZYME) - 2024 Q4 - Annual Results

Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026 Vancouver, British Columbia (January 08, 2025) – Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today provided an update on key strategic priorities for 2025 and 2026. "2024 was a pivotal year for Zymeworks, marked by the firs ...